473 related articles for article (PubMed ID: 36280532)
1. Development of mRNA vaccines against respiratory syncytial virus (RSV).
Qiu X; Xu S; Lu Y; Luo Z; Yan Y; Wang C; Ji J
Cytokine Growth Factor Rev; 2022 Dec; 68():37-53. PubMed ID: 36280532
[TBL] [Abstract][Full Text] [Related]
2. [Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?].
Novoa Pizarro JM; Lindemann Tappert BC; Luchsinger Farías VR; Vargas Munita SL
Andes Pediatr; 2023 Dec; 94(6):672-680. PubMed ID: 38329302
[TBL] [Abstract][Full Text] [Related]
3. The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.
Frenkel LD; Gaur S; Bellanti JA
Allergy Asthma Proc; 2023 Jul; 44(4):220-228. PubMed ID: 37236777
[No Abstract] [Full Text] [Related]
4. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
[TBL] [Abstract][Full Text] [Related]
5. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
6. The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.
Shan J; Britton PN; King CL; Booy R
Influenza Other Respir Viruses; 2021 Jul; 15(4):539-551. PubMed ID: 33764693
[TBL] [Abstract][Full Text] [Related]
7. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.
Xue M; Wang R; Harder O; Chen P; Lu M; Cai H; Li A; Liang X; Jennings R; La Perle K; Niewiesk S; Peeples ME; Li J
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999025
[TBL] [Abstract][Full Text] [Related]
8. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
[TBL] [Abstract][Full Text] [Related]
9. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
10. Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
Comeaux CA; Bart S; Bastian AR; Klyashtornyy V; De Paepe E; Omoruyi E; van der Fits L; van Heesbeen R; Heijnen E; Callendret B; Sadoff J
J Infect Dis; 2024 Jan; 229(1):19-29. PubMed ID: 37433021
[TBL] [Abstract][Full Text] [Related]
11. Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease.
Kotomina T; Isakova-Sivak I; Matyushenko V; Kim KH; Lee Y; Jung YJ; Kang SM; Rudenko L
Antiviral Res; 2019 Aug; 168():9-17. PubMed ID: 31075351
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
Wilson E; Goswami J; Baqui AH; Doreski PA; Perez-Marc G; Zaman K; Monroy J; Duncan CJA; Ujiie M; Rämet M; Pérez-Breva L; Falsey AR; Walsh EE; Dhar R; Wilson L; Du J; Ghaswalla P; Kapoor A; Lan L; Mehta S; Mithani R; Panozzo CA; Simorellis AK; Kuter BJ; Schödel F; Huang W; Reuter C; Slobod K; Stoszek SK; Shaw CA; Miller JM; Das R; Chen GL;
N Engl J Med; 2023 Dec; 389(24):2233-2244. PubMed ID: 38091530
[TBL] [Abstract][Full Text] [Related]
13. Development and qualification of cell-based relative potency assay for a human respiratory syncytial virus (RSV) mRNA vaccine.
Li HH; Xu J; He L; Denny LI; Rustandi RR; Dornadula G; Fiorito B; Zhang ZQ
J Pharm Biomed Anal; 2023 Sep; 234():115523. PubMed ID: 37336039
[TBL] [Abstract][Full Text] [Related]
14. The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.
Kurai D; Mizukami A; Preckler V; Verelst F; Molnar D; Matsuki T; Ho Y; Igarashi A
Expert Rev Vaccines; 2024; 23(1):303-311. PubMed ID: 38426479
[TBL] [Abstract][Full Text] [Related]
15. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.
Scotta MC; Stein RT
J Pediatr (Rio J); 2023; 99 Suppl 1(Suppl 1):S4-S11. PubMed ID: 36402228
[TBL] [Abstract][Full Text] [Related]
16. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A; Ison MG; Langley JM; Lee DG; Leroux-Roels I; Martinon-Torres F; Schwarz TF; van Zyl-Smit RN; Campora L; Dezutter N; de Schrevel N; Fissette L; David MP; Van der Wielen M; Kostanyan L; Hulstrøm V;
N Engl J Med; 2023 Feb; 388(7):595-608. PubMed ID: 36791160
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older.
Eto T; Okubo Y; Momose A; Tamura H; Zheng R; Callendret B; Bastian AR; Comeaux CA
Influenza Other Respir Viruses; 2024 Jun; 18(6):e13336. PubMed ID: 38880785
[TBL] [Abstract][Full Text] [Related]
18. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey I; Saelens X
Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
[No Abstract] [Full Text] [Related]
19. Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children.
McFarland EJ; Karron RA; Muresan P; Cunningham CK; Perlowski C; Libous J; Oliva J; Jean-Philippe P; Moye J; Schappell E; Barr E; Rexroad V; Fearn L; Cielo M; Wiznia A; Deville JG; Yang L; Luongo C; Collins PL; Buchholz UJ
J Infect Dis; 2020 Jun; 221(12):2050-2059. PubMed ID: 32006006
[TBL] [Abstract][Full Text] [Related]
20. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.
Mazur NI; Higgins D; Nunes MC; Melero JA; Langedijk AC; Horsley N; Buchholz UJ; Openshaw PJ; McLellan JS; Englund JA; Mejias A; Karron RA; Simões EA; Knezevic I; Ramilo O; Piedra PA; Chu HY; Falsey AR; Nair H; Kragten-Tabatabaie L; Greenough A; Baraldi E; Papadopoulos NG; Vekemans J; Polack FP; Powell M; Satav A; Walsh EE; Stein RT; Graham BS; Bont LJ;
Lancet Infect Dis; 2018 Oct; 18(10):e295-e311. PubMed ID: 29914800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
